International Council for Standardization in Haematology field study evaluating optimal interpretation methods for activated partial thromboplastin time and prothrombin time mixing studies

Article


Gosselin, R.C., Moore, G.W., Kershaw, G.W., Montalvão, S. and Adcock, D.M. 2023. International Council for Standardization in Haematology field study evaluating optimal interpretation methods for activated partial thromboplastin time and prothrombin time mixing studies. Archives of Pathology & Laboratory Medicine. 148 (8), pp. 880-889. https://doi.org/10.5858/arpa.2023-0030-oa
TypeArticle
TitleInternational Council for Standardization in Haematology field study evaluating optimal interpretation methods for activated partial thromboplastin time and prothrombin time mixing studies
AuthorsGosselin, R.C., Moore, G.W., Kershaw, G.W., Montalvão, S. and Adcock, D.M.
Abstract

Context.—
The prothrombin time (PT) and activated partial thromboplastin time (APTT) are screening tests used to detect congenital or acquired bleeding disorders. An unexpected PT and/or APTT prolongation is often evaluated using a mixing test with normal plasma. Failure to correct (“noncorrection”) prolongation upon mixing is attributed to an inhibitor, whereas “correction” points to factor deficiency(ies).

Objective.—
To define an optimal method for determining correction or noncorrection of plasma mixing tests through an international, multisite study that used multiple PT and APTT reagents and well-characterized plasma samples.

Design.—
Each testing site was provided 22 abnormal and 25 normal donor plasma samples, and mixing studies were performed using local PT and APTT reagents. Mixing study results were evaluated using 11 different calculation methods to assess the optimal method based on the expected interpretation for factor deficiencies (correction) and noncorrection (inhibitor effect). Misprediction, which represents the failure of a mixing study interpretation method, was assessed.

Results.—
Percentage correction was the most suitable calculation method for interpreting PT mixing test results for nearly all reagents evaluated. Incubated PT mixing tests should not be performed. For APTT mixing tests, percentage correction should be performed, and if the result indicates a factor deficiency, this should be confirmed with the subtraction III calculation where the normal pooled plasma result (run concurrently) is subtracted from the mixing test result with correction indicated by a result of 0 or less. In general, other calculation methods evaluated that performed well in the identification of factor deficiency tended to have high misprediction rates for inhibitors and vice versa.

Conclusions.—
No single method of mixing test result calculation was consistently successful in accurately distinguishing factor deficiencies from inhibitors, with between-reagent and between-site variability also identified.

Sustainable Development Goals3 Good health and well-being
Middlesex University ThemeHealth & Wellbeing
PublisherCollege of American Pathologists
JournalArchives of Pathology & Laboratory Medicine
ISSN0003-9985
Electronic1543-2165
Publication dates
Online28 Nov 2023
Print01 Aug 2024
Publication process dates
Accepted18 Sep 2023
Deposited12 Dec 2025
Output statusPublished
Digital Object Identifier (DOI)https://doi.org/10.5858/arpa.2023-0030-oa
Permalink -

https://repository.mdx.ac.uk/item/30z117

  • 39
    total views
  • 0
    total downloads
  • 1
    views this month
  • 0
    downloads this month

Export as

Related outputs

Diagnosing thrombophilia: the case for genetic or functional testing?
Favaloro, E.J., Moore, G.W. and Pasalic, L. 2025. Diagnosing thrombophilia: the case for genetic or functional testing? Expert Review of Molecular Diagnostics. 25 (12), pp. 841-846. https://doi.org/10.1080/14737159.2025.2588621
Survey on current practice in thrombophilia testing: from phenotype to genotype. Communication from the SSC of the ISTH
Van Laer, C., Moore, G.W., Majumder, R., Corral, J., Freson, K., Ignjatovic, V. and Orlando, C. 2025. Survey on current practice in thrombophilia testing: from phenotype to genotype. Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.10.032
International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests
Adcock, D.M., Moore, G., Kershaw, G.W., Montalvao, S. and Gosselin, R. 2024. International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests. International Journal of Laboratory Hematology. 46 (5), pp. 777-788. https://doi.org/10.1111/ijlh.14344
Analytical dilemmas in lupus anticoagulant detection
Moore, G. 2023. Analytical dilemmas in lupus anticoagulant detection. Exploration of Immunology. 3, pp. 300-324. https://doi.org/10.37349/ei.2023.00104
ADAMTS13 activity measurement by ELISA and fluorescence resonance energy transfer assay
Moore, G., Llusa, M., Griffiths, M. and Binder, N. 2023. ADAMTS13 activity measurement by ELISA and fluorescence resonance energy transfer assay. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
ADAMTS13 activity: Screening test protocol
Moore, G., Griffiths, M. and Binder, N. 2023. ADAMTS13 activity: Screening test protocol. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
Lupus anticoagulant testing: Dilute prothrombin time (dPT)
Moore, G. 2023. Lupus anticoagulant testing: Dilute prothrombin time (dPT). in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
Lupus anticoagulant testing: Taipan snake venom time with ecarin time as confirmatory test
Moore, G. 2023. Lupus anticoagulant testing: Taipan snake venom time with ecarin time as confirmatory test. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
ADAMTS13 antibody and inhibitor assays
Moore, G., Vetr, H. and Binder, N. 2023. ADAMTS13 antibody and inhibitor assays. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art
Adcock, D., Moore, G., Montalvão, S., Kershaw, G. and Gosselin, R. 2022. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art. Seminars in Thrombosis and Hemostasis. 49 (6), pp. 571-579. https://doi.org/10.1055/s-0042-1756196
Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
Vandevelde, A., Chayoua, W., de Laat, B., Moore, G., Musiał, J., Zuily, S., Wahl, D. and Devreese, K. 2022. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Journal of Thrombosis and Haemostasis. 20 (9), pp. 2136-2150. https://doi.org/10.1111/jth.15785
Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study
Fisher, R., Moore, G., Mitchell, M., Dai, L., Crichton, S., Lumlertgul, N. and Ostermann, M. 2022. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Annals of Intensive Care. 12 (1), pp. 1-11. https://doi.org/10.1186/s13613-022-01004-w
Direct oral anticoagulants‐Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors
White, D., Moore, G., Besser, M., MacDonald, S. and Thomas, W. 2022. Direct oral anticoagulants‐Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors. Research and Practice in Thrombosis and Haemostasis. 6 (1), pp. 1-8. https://doi.org/10.1002/rth2.12648
Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies
Vandevelde, A., Chayoua, W., de Laat, B., Gris, J., Moore, G., Musiał, J., Zuily, S., Wahl, D. and Devreese, K. 2022. Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies. Journal of Thrombosis and Haemostasis. 20 (2), pp. 508-524. https://doi.org/10.1111/jth.15585
Snake venoms in diagnostic hemostasis and thrombosis
Moore, G. 2022. Snake venoms in diagnostic hemostasis and thrombosis. Seminars in Thrombosis and Hemostasis. 48 (02), pp. 145-160. https://doi.org/10.1055/s-0041-1732465
International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies
Moore, G., Jones, P., Platton, S., Hussain, N., White, D., Thomas, W., Rigano, J., Pouplard, C., Gray, E. and Devreese, K. 2021. International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies. Journal of Thrombosis and Haemostasis. 19 (12), pp. 3177-3192. https://doi.org/10.1111/jth.15438
Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors
Kumano, O., Amiral, J., Dunois, C., Peyrafitte, M. and Moore, G. 2021. Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors. International Journal of Laboratory Hematology. 43 (4), pp. 771-778. https://doi.org/10.1111/ijlh.13571
Clinical validation of an automated fluorogenic factor XIII activity assay based on isopeptidase activity
Leitner, M., Büchold, C., Pasternack, R., Binder, N. and Moore, G. 2021. Clinical validation of an automated fluorogenic factor XIII activity assay based on isopeptidase activity. International Journal of Molecular Sciences. 22 (3). https://doi.org/10.3390/ijms22031002